Federica Marchesi

Dr. Federica Marchesi


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2017 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
Alberto MantovaniAlberto Mantovani
Alberto Mantovani
FMFederica Marchesi
Federica Marchesi
AMAlberto Malesci
Alberto Malesci
LLLuigi Laghi
Luigi Laghi
PAPaola Allavena
Paola Allavena

16 August 2022 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
Alberto MantovaniAlberto Mantovani
Alberto Mantovani
PAPaola Allavena
Paola Allavena
FMFederica Marchesi
Federica Marchesi
CGCecilia Garlanda
Cecilia Garlanda

15 July 2005 in Blood
Verified
Journal Article
Closed access
PDF file
VSValeria Sordi
Valeria Sordi
MMMARIA LUISA MALOSIO
MARIA LUISA MALOSIO
FMFederica Marchesi
Federica Marchesi
AMAlessia Mercalli
Alessia Mercalli
RMRaffaella Melzi
Raffaella Melzi
LPLorenzo Piemonti
Lorenzo Piemonti
Bone marrow–derived mesenchymal stem cells (BM-MSCs) are stromal cells with the ability to proliferate and differentiate into many tissues. Although they represent powerful tools for several therapeutic settings, mechanisms regulating their migration to peripheral tissues are still unknown. Here, we report chemokine receptor expression on human BM-MSCs and their role in mediating migration to tissues. A minority of BM-MSCs (2% to 25%) expressed a restricted set of chemokine receptors (CXC receptor 4 [CXCR4], CX3C receptor 1 [CX3CR1], CXCR6, CC chemokine receptor 1 [CCR1], CCR7) and, accordingly, showed appreciable chemotactic migration in response to the chemokines CXC ligand 12 (CXCL12), CX3CL1, CXCL16, CC chemokine ligand 3 (CCL3), and CCL19. Using human pancreatic islets as an in vitro model of peripheral tissue, we showed that islet supernatants released factors able to attract BM-MSCs in vitro, and this attraction was principally mediated by CX3CL1 and CXCL12. Moreover, cells with features of BM-MSCs were detected within the pancreatic islets of mice injected with green fluorescent protein (GFP)–positive BM. A population of bona fide MSCs that also expressed CXCR4, CXCR6, CCR1, and CCR7 could be isolated from normal adult human pancreas. This study defines the chemokine receptor repertoire of human BM-MSCs that determines their migratory activity. Modulation of homing capacity may be instrumental for harnessing the therapeutic potential of BM-MSCs.

15 April 2014 in Clinical Cancer Research
Verified
Journal Article
Closed access
GCGiuseppe Di Caro
Giuseppe Di Caro
FBFrancesca Bergomas
Francesca Bergomas
Fabio GrizziFabio Grizzi
Fabio Grizzi
Andrea DoniAndrea Doni
Andrea Doni
PBPaolo Bianchi
Paolo Bianchi
FMFederica Marchesi
Federica Marchesi
Purpose: Tumor-infiltrating T lymphocytes (TIL) play a key role in the clinical outcome of human colorectal cancer; however, the dynamics of their recruitment along colorectal cancer clinical progression have not been fully elucidated. Tertiary lymphoid tissue (TLT) is an ectopic organized lymph node–like structure that typically forms at sites of chronic inflammation and is involved in adaptive immune responses. Its occurrence in cancer is sporadically documented and its role and clinical relevance is largely unknown. Experimental Design: The occurrence of TLT, the correlation with TILs, and the clinical relevance were evaluated retrospectively, in a cohort study involving a consecutive series of 351 patients with stage II and III colorectal cancer. The role of TLT in lymphocyte recruitment was assessed in a preclinical model of colorectal cancer. Results: In both human colorectal cancer and in a murine model of colorectal cancer, we identified organized TLT, highly vascularized (including high endothelial venules), and correlated with the density of CD3+ TILs. Intravenous injection in mice of GFP splenocytes resulted in homing of lymphocytes to TLT, suggesting an active role of TLT in the recruitment of lymphocytes to tumor areas. Accordingly, TLT density and TIL infiltration correlated and were coordinated in predicting better patient's outcome among patients with stage II colorectal cancer. Conclusions: We provide evidence that TLT is associated with lymphocyte infiltration in colorectal cancer, providing a pathway of recruitment for TILs. TLT cooperates with TILs in a coordinated antitumor immune response, when identifying patients with low-risk early-stage colorectal cancer, thus, representing a novel prognostic biomarker for colorectal cancer. Clin Cancer Res; 20(8); 2147–58. ©2014 AACR.

3 October 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MBMaria Grazia Borrello
Maria Grazia Borrello
LALuisella Alberti
Luisella Alberti
AFAndrew H. Fischer
Andrew H. Fischer
DDDebora Degl'INnocenti
Debora Degl'INnocenti
CFCristina Ferrario
Cristina Ferrario
MPMarco A. Pierotti
Marco A. Pierotti
Rearrangements of the RET receptor tyrosine kinase gene generating RET / PTC oncogenes are specific to papillary thyroid carcinoma (PTC), the most frequent thyroid tumor. Here, we show that the RET / PTC1 oncogene, when exogenously expressed in primary normal human thyrocytes, induces the expression of a large set of genes involved in inflammation and tumor invasion, including those encoding chemokines (CCL2, CCL20, CXCL8, and CXCL12), chemokine receptors (CXCR4), cytokines (IL1B, CSF-1, GM-CSF, and G-CSF), matrix-degrading enzymes (metalloproteases and urokinase-type plasminogen activator and its receptor), and adhesion molecules (L-selectin). This effect is strictly dependent on the presence of the RET/PTC1 Tyr-451 (corresponding to RET Tyr-1062 multidocking site). Selected relevant genes ( CCL20 , CCL2 , CXCL8 , CXCR4 , L-selectin , GM-CSF , IL1B , MMP9 , UPA , and SPP1 / OPN ) were found up-regulated also in clinical samples of PTC, particularly those characterized by RET / PTC activation, local extrathyroid spread, and lymph node metastases, when compared with normal thyroid tissue or follicular thyroid carcinoma. These results, demonstrating that the RET / PTC1 oncogene activates a proinflammatory program, provide a direct link between a transforming human oncogene, inflammation, and malignant behavior.

15 November 2004 in Cancer Research
Verified
Journal Article
Open access
PDF file
FMFederica Marchesi
Federica Marchesi
MPMonti Paolo
Monti Paolo
BLBiagio Eugenio Leone
Biagio Eugenio Leone
AZAlessandro Zerbi
Alessandro Zerbi
AVAnnunciata Vecchi
Annunciata Vecchi
PAPaola Allavena
Paola Allavena
In this study, we have evaluated 11 pancreatic tumor cell lines and tumor cells from surgical samples of patients with pancreatic adenocarcinoma for expression of the chemokine receptor CXCR4. Six of 11 cell lines expressed detectable mRNA of CXCR4, with three cell lines (AsPC1, Capan1, and Hs766T) having substantial amounts of transcripts. Expression was higher in lines derived from metastatic lesions compared with those derived from primary tumors. Different inflammatory cytokines did not modify expression, whereas IFN-γ down-regulated and hypoxia up-regulated CXCR4 transcripts. Transcript expression was associated with surface expression in pancreatic carcinoma cell lines. All surgical carcinoma samples tested expressed higher levels of CXCR4 than normal pancreatic ducts, which were used as reference tissue. The chemokine CXCL12 induced chemotaxis in CXCR4-positive pancreatic carcinoma cell lines, which was inhibited by anti-CXCR4 monoclonal antibody and by the antagonist AMD3100. Transendothelial migration, Matrigel invasion, and activation of matrix metalloproteases were also enhanced by CXCL12. In CXCR4-positive cell lines, CXCL12 stimulated cell proliferation. The cell line Hs766T produces high levels of CXCL12, and addition of the CXCR4 antagonist AMD3100 partially inhibited proliferation, indicating an autocrine loop. Moreover, the addition of exogenous CXCL12 inhibited apoptosis induced by serum starvation. These results indicate that the CXCR4 receptor is frequently expressed in metastatic pancreatic tumor cells. CXCR4 not only stimulates cell motility and invasion but also promotes survival and proliferation. Strategies to target CXCR4 expressed on tumor cells may be of benefit in patients with pancreatic cancer.